Coenzyme Q10: a progress towards the treatment of neurodegenerativedisease > Volume 10 - 2010

본문 바로가기

사이트 내 전체검색

 » New Articles(2011~Present)
 » Articles (2001~2010)
      ∙ Volume 10 - 2010
      ∙ Volume 09 - 2009
      ∙ Volume 08 - 2008
      ∙ Volume 07 - 2007
      ∙ Volume 06 - 2006
      ∙ Volume 05 - 2005
      ∙ Volume 04 - 2004
      ∙ Volume 03 - 2003
      ∙ Volume 02 - 2002
      ∙ Volume 01 - 2001

Oriental Pharmacy and Experimental Medicine
Volume 10 - 2010
Date: September 15, 2010

Journal: Pages 239-253

December 2010 | Coenzyme Q10: a progress towards the treatment of neurodegenerativedisease…

Peeyush kumar1,*, Pramod kumar1, Alpana ram1, Mithilesh kumar2 and Rajeev kumar2



​Coenzyme Q10 (CoQ10, or ubiquinone) is an electron carrier of the mitochondrial respiratory chain(electron transport chain) with antioxidant properties. In view of the involvement of CoQ10 inoxidative phosphorylation and cellular antioxidant protection a deficiency in this quinone wouldbe expected to contribute to disease pathophysiology by causing a failure in energy metabolismand antioxidant status. Indeed, a deficit in CoQ10 status has been determined in a number ofneuromuscular and neurodegenerative disorders. Primary disorders of CoQ10 biosynthesis arepotentially treatable conditions and therefore a high degree of clinical awareness about thiscondition is essential. A secondary loss of CoQ10 status following HMG-CoA reductase inhibitor(statins) treatment has been implicated in the pathophysiology of the myotoxicity associated withthis pharmacotherapy. CoQ10 and its analogue, idebenone, have been widely used in the treatment ofneurodegenerative and neuromuscular disorders. These compounds could potentially play a rolein the treatment of mitochondrial disorders, Parkinson’s disease, Huntington’s disease, amyotrophiclateral sclerosis, Friedreich’s ataxia, and other conditions which have been linked to mitochondrialdysfunction. This article reviews the physiological roles of CoQ10, as well as the rationale and therole in clinical practice of CoQ10 supplementation in different neurological diseases, from primaryCoQ10 deficiency to neurodegenerative disorders. These will help in future for treatment ofpatients suffering from neurodegenerative disease.

This website Copyright (c) 2014 Institute of Korean Medicine Kyung Hee University All rights reserved.
Top View
Mobile View